Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan

Podos S.D.a · Trachtman H.b · Appel G.B.c · Bomback A.S.c · Dixon B.P.d · Wetzels J.F.M.e · Cook H.T.f · Parikh S.V.g · Pickering M.C.f · Tumlin J.h · Langman C.B.i · Lightstone L.f · Sperati C.J.j · Daina E.k · Bouman K.P.l · Rice K.m · Thanassi J.A.a · Huang M.a · Nester C.n · Remuzzi G.k

doi : 10.1159/000527166

Vol. 53, No. 10, 2022

C3 glomerulopathy (C3G) is a rare, progressive kidney disease resulting from dysregulation of the alternative pathway (AP) of complement. Biomarkers at baseline were investigated in patients with C3G who participated in two phase 2 studies with the factor D (FD) inhibitor, danicopan.

خرید پکیج و مشاهده آنلاین مقاله

Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies

Nester C.a · Appel G.B.b · Bomback A.S.b · Bouman K.P.c · Cook H.T.d · Daina E.e · Dixon B.P.f · Rice K.g · Najafian N.g · Hui J.g · Podos S.D.h · Langman C.B.i · Lightstone L.d · Parikh S.V.j · Pickering M.C.d · Sperati C.J.k · Trachtman H.l · Tumlin J.m · de Vries A.P.J.n · Wetzels J.F.M.o · Remuzzi G.e

doi : 10.1159/000527167

C3 glomerulopathy (C3G) is an ultrarare, chronic and progressive nephropathy mediated by dysregulation of the alternative pathway of complement (AP), with poor prognosis and limited treatment options.

خرید پکیج و مشاهده آنلاین مقاله

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials

Agarwal R.a · Anand S.b · Eckardt K.-U.c · Luo W.b · Parfrey P.S.d · Sarnak M.J.e · Solinsky C.M.b · Vargo D.L.b · Winkelmayer W.C.f · Chertow G.M.g

doi : 10.1159/000528443

Anemia frequently occurs in chronic kidney disease (CKD), is associated with poor quality of life and cardiovascular outcomes, and its treatment represents a considerable economic burden to the healthcare system.

خرید پکیج و مشاهده آنلاین مقاله

Hemodialysis Effects on Autonomic Function: Results of Linear and Nonlinear Analysis of Heart Rate Variability at Rest and in Response to Physical and Mental Stress Tests

Faitatzidou D.a · Dipla K.b · Theodorakopoulou M.P.a · Koutlas A.b · Karagiannidis A.a · Alexandrou M.-E.a · Tsouchnikas I.a · Giamalis P.a · Dimitriadis C.a · Zafeiridis A.b · Papagianni A.a · Sarafidis P.a

doi : 10.1159/000528322

Cardiac arrhythmias are the most common cause of death in hemodialysis. Autonomic dysfunction plays a central role in this arrhythmogenic background. Previous studies on hemodialysis-related changes in heart rate variability (HRV) give contradictory results.

خرید پکیج و مشاهده آنلاین مقاله

Factors Affecting the Decision to Initiate Dialysis: A National Survey of United States Nephrologists

Mathur V.S.a · Wesson D.E.b · Li E.c · Tangri N.d

doi : 10.1159/000528167

The percentage of patients initiating dialysis at an estimated glomerular filtration rate (eGFR) ≤9 mL/min/1.73 m2 decreased between 2000 and 2018 in the USA.

خرید پکیج و مشاهده آنلاین مقاله

Cardiovascular Risk Prediction in Chronic Kidney Disease

Li X.a,b · Lindholm B.b

doi : 10.1159/000528560

As one of the main complications of chronic kidney disease (CKD), the incidence of cardiovascular disease (CVD) in CKD patients is high. CVD risk is markedly increased even at early stages of CKD, and CVD deaths account for half of all known causes of mortality in end-stage renal disease patients.

خرید پکیج و مشاهده آنلاین مقاله

Metabolic Basis and Pathogenesis of Skeletal Muscle Dysfunction as Cause of Frailty in Chronic Kidney Disease

Wesson D.E.a · Mathur V.b · Tangri N.c

doi : 10.1159/000526679

Frailty is common in patients with chronic kidney disease (CKD), as is its physical component, phenotypic frailty, and each contributes to CKD-related disability and are associated with increased mortality.

خرید پکیج و مشاهده آنلاین مقاله

Proteinuria and Risk for Heart Failure in 55,191 Patients Having History of Cancer

Suzuki Y.a,b · Kaneko H.a,c · Okada A.d · Fujiu K.a,c · Michihata N.e · Jo T.e · Takeda N.a · Morita H.a · Kamiya K.f · Matsunaga A.f · Ako J.g · Node K.h · Nangaku M.i · Yasunaga H.j · Komuro I.a

doi : 10.1159/000527703

We examined the association of proteinuria with the risk for heart failure (HF) and other cardiovascular disease (CVD) events in patients with prior history of breast, colorectal, or stomach cancer using a nationwide population-based database.

خرید پکیج و مشاهده آنلاین مقاله

Clinical Effectiveness of Calcium Oxalate Stone Treatments

Gutbrod J. · Keys McKay C.C. · Coe L. · Bergsland K. · Coe F. · Worcester E. · Prochaska M.

doi : 10.1159/000527940

Lowering kidney stone risk and urine calcium oxalate supersaturation is a primary clinical focus for kidney stone prevention and can be achieved with multiple strategies. Common strategies include advice to increase fluid intake, restrict dietary sodium, or prescribing a thiazide-type diuretic.

خرید پکیج و مشاهده آنلاین مقاله